Immutep Competitors

Stocks USA . 
Stock . Immutep Ltd ADR
IMMP Stock  USD 3.10  0.14  4.73%   
Immutep Ltd ADR competes with Morningstar Unconstrained, Victory Sophus, Spring Valley, CarMax, and SEI Investments; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Immutep competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Immutep to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Immutep Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Immutep competition on your existing holdings.
  
As of 05/22/2024, Return On Tangible Assets is likely to drop to -0.27. In addition to that, Return On Capital Employed is likely to drop to -0.31. At this time, Immutep's Total Assets are relatively stable compared to the past year. As of 05/22/2024, Other Current Assets is likely to grow to about 4.3 M, while Return On Tangible Assets are likely to drop (0.27).
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Immutep's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.163.106.84
Details
Intrinsic
Valuation
LowRealHigh
0.142.886.62
Details
Naive
Forecast
LowNextHigh
0.063.026.76
Details
4 Analysts
Consensus
LowTargetHigh
6.917.598.42
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Immutep. Your research has to be compared to or analyzed against Immutep's peers to derive any actionable benefits. When done correctly, Immutep's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Immutep Ltd ADR.

Immutep Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Immutep and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Immutep and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Immutep Ltd ADR does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
SEIC
+ 0.84
KMX
GBEMX
+ 0.83
MSTSX
SVII
+ 0.7
GBEMX
SEIC
+ 0.5
MSTSX
SVII
+ 0.41
MSTSX
EMBC
+ 0.32
KMX
  
High negative correlations   
WLDSW
- 0.61
MSTSX
EMBC
- 0.56
SVII
WLDSW
- 0.53
GBEMX
WLDSW
- 0.52
SVII
KMX
- 0.48
SVII
SEIC
- 0.19
SVII

Risk-Adjusted Indicators

There is a big difference between Immutep Stock performing well and Immutep Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Immutep's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Cross Equities Net Income Analysis

Compare Immutep Ltd ADR and related stocks such as Morningstar Unconstrained, Victory Sophus Emerging, and Spring Valley Acquisition Net Income Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
SVII(12.4 K)(12.4 K)(12.4 K)(12.4 K)(12.4 K)(12.4 K)(12.4 K)(12.4 K)(12.4 K)(12.4 K)(12.4 K)(12.4 K)1.4 M11 M11.5 M
KMX(9.3 M)434.3 M434.3 M492.6 M597.4 M627 M627 M664.1 M842.4 M746.9 M746.9 M1.2 B484.8 M479.2 M396.4 M
SEIC3.8 M205 M206.8 M288.1 M318.7 M331.7 M333.8 M404.4 M505.9 M501.4 M447.3 M546.6 M475.5 M462.3 M485.4 M
EMBC432 M432 M432 M432 M432 M432 M432 M432 M432 M427.6 M414.8 M223.6 M70.4 M63.4 M60.2 M
WLDSW(1 M)(1 M)(1 M)(1 M)(1 M)(1 M)(1 M)(1 M)(1 M)(1 M)(1.3 M)(2.6 M)(6.5 M)(7.8 M)(7.4 M)

Immutep Ltd ADR and related stocks such as Morningstar Unconstrained, Victory Sophus Emerging, and Spring Valley Acquisition Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Immutep Ltd ADR financial statement analysis. It represents the amount of money remaining after all of Immutep Ltd ADR operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Immutep Competitive Analysis

The better you understand Immutep competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Immutep's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Immutep's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
IMMP MSTSX GBEMX SVII KMX SEIC EMBC WLDSW
 4.73 
 3.10 
Immutep
 0.09 
 11.15 
Morningstar
 0.64 
 20.32 
VICTORY
 0.18 
 11.08 
Spring
 0.83 
 71.97 
CarMax
 0.71 
 68.45 
SEI
 1.72 
 13.69 
Embecta
 24.44 
 0.05 
Wearable
Market Volatility
(90 Days Market Risk)
Risky
Very steady
Very steady
Very steady
Very steady
Very steady
Slightly risky
Out of control
Market Performance
(90 Days Performance)
Good
Good
Good
Good
Weak
Modest
Very Weak
Insignificant
Odds of Financial Distress
(Probability Of Bankruptcy)
Below Average
Low
Low
Above Average
Low
Low
Low
Very High
Current Valuation
(Equity Enterprise Value)
Over Valued
Fairly Valued
Fairly Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Fairly Valued
Buy or Sell Advice
(Average Analysts Consensus)
Strong Buy
Not Available
Not Available
Not Available
Buy
Hold
Hold
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Hold
Buy
Hold
Strong Sell
Sell
Strong Hold
Strong Sell
Strong Sell
Current Ratio
14.16 X
N/A
N/A
N/A
2.75 X
4.43 X
2.54 X
2.20 X
Net Asset
147.45 M
116.1 M
397.89 M
250.58 M
27.52 B
2.52 B
1.21 B
7.59 M
Profit Margin
N/A
N/A
N/A
N/A
0.02 %
0.25 %
0.06 %
N/A
EBITDA
(42.88 M)
N/A
N/A
(875.46 K)
154.1 M
424.52 M
247.8 M
(8.12 M)
Operating Margin
(10.96) %
N/A
N/A
N/A
0.02 %
0.25 %
0.25 %
(59.03) %
Current Valuation
3.74 B
N/A
N/A
246.2 M
30.28 B
8.14 B
2.16 B
N/A
Price To Book
3.93 X
N/A
1.61 X
1.01 X
1.85 X
4.16 X
2.61 X
N/A
Retained Earnings
(339.93 M)
N/A
N/A
(6.9 M)
4.13 B
762.59 M
(541.1 M)
(21.22 M)
Current Asset
1.89 M
N/A
N/A
N/A
2.47 B
1 B
N/A
N/A
Five Year Return
N/A
9.03 %
3.11 %
N/A
N/A
1.18 %
N/A
N/A
One Year Return
N/A
17.63 %
14.18 %
N/A
N/A
N/A
N/A
N/A
Beta
1.79
N/A
N/A
N/A
1.64
1.03
0.82
N/A
Cash Position Weight
N/A
14.28 %
1.02 %
N/A
N/A
N/A
N/A
N/A
Equity Positions Weight
N/A
61.63 %
98.98 %
N/A
N/A
N/A
N/A
N/A
Number Of Employees
N/A
1
1
N/A
29.84 K
5.06 K
2.2 K
29
Shares Outstanding
118.88 M
N/A
N/A
22.3 M
157.33 M
131.39 M
57.67 M
N/A
Three Year Return
N/A
5.49 %
(6.93) %
N/A
N/A
N/A
N/A
N/A
Cash Flow From Operations
(35.88 M)
N/A
N/A
(491.06 K)
458.62 M
447.03 M
67.7 M
(8.43 M)
Annual Yield
N/A
0.02 %
0.02 %
N/A
N/A
0.01 %
0.04 %
N/A
Total Debt
1.23 M
N/A
N/A
269.09 K
19.53 B
25.35 M
1.64 B
575 K
Return On Equity
-0.42
N/A
N/A
N/A
0.082
0.23
N/A
-1.01
Bond Positions Weight
N/A
22.72 %
N/A
N/A
N/A
N/A
N/A
N/A
Holdings Turnover
N/A
269.00 %
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.26
N/A
N/A
-0.0029
0.0177
0.12
0.0974
-0.54
Number Of Shares Shorted
2.69 M
N/A
N/A
4.78 K
19.69 M
1.78 M
2.66 M
N/A
Book Value Per Share
0.1 X
N/A
N/A
(0.99) X
38.54 X
17.20 X
(13.35) X
(0.08) X
Current Liabilities
1.04 M
N/A
N/A
N/A
1.01 B
224.48 M
N/A
N/A
Total Asset
147.45 M
215.11 M
38.26 M
250.58 M
27.52 B
2.52 B
1.21 B
7.59 M
Debt To Equity
0.02 %
N/A
N/A
N/A
3.59 %
0.01 %
N/A
N/A
Short Ratio
9.34 X
N/A
N/A
0.31 X
6.67 X
3.33 X
6.93 X
N/A
Target Price
8.27
N/A
N/A
N/A
78.14
73.0
15.0
N/A
Last Dividend Paid
N/A
N/A
0.04
N/A
N/A
0.89
0.6
N/A
Shares Owned By Institutions
2.86 %
N/A
N/A
69.20 %
99.67 %
74.04 %
98.90 %
N/A
Market Capitalization
383.99 M
50.36 M
N/A
246.69 M
11.32 B
8.99 B
803.35 M
N/A
Price To Earning
(152.55) X
N/A
10.86 X
N/A
14.73 X
19.70 X
4.91 X
N/A
Price To Earnings To Growth
N/A
N/A
N/A
N/A
0.90 X
1.43 X
N/A
N/A
Price To Sales
75.31 X
N/A
1.07 X
N/A
0.40 X
4.62 X
0.53 X
N/A
Net Income
(39.9 M)
N/A
N/A
10.97 M
479.2 M
462.26 M
70.4 M
(7.81 M)
Earnings Per Share
(0.31) X
N/A
N/A
0.37 X
3.02 X
3.66 X
1.22 X
N/A
Shares Owned By Insiders
0.01 %
N/A
N/A
68.74 %
0.33 %
23.69 %
0.46 %
N/A
Revenue
3.51 M
N/A
N/A
N/A
26.54 B
1.92 B
1.12 B
82 K
Year To Date Return
N/A
7.81 %
7.22 %
N/A
N/A
N/A
N/A
N/A
Working Capital
125.19 M
N/A
N/A
1.15 M
2.91 B
1.13 B
395.6 M
4.96 M
Ten Year Return
N/A
N/A
1.66 %
N/A
N/A
N/A
N/A
N/A
Cash And Equivalents
80 M
N/A
N/A
N/A
102.72 M
791.44 M
292.3 M
1.27 M
Cash Per Share
0.92 X
N/A
N/A
N/A
0.36 X
5.87 X
5.05 X
0.11 X
Gross Profit
(32.75 M)
N/A
N/A
N/A
2.8 B
1.58 B
774.9 M
N/A
Day Typical Price
3.08
11.15
20.32
11.08
72.1
68.26
13.74
0.0499
Accumulation Distribution
0.057
N/A
N/A
6.21
30100.74
4359.2
13625.14
2.0
Market Facilitation Index
0.18
N/A
N/A
0.0
0.0
0.0
0.0
N/A
Daily Balance Of Power
0.7778
(9,223,372,036,855)
(9,223,372,036,855)
2.0
(0.44)
0.6234
(0.50)
98.0
Period Momentum Indicator
0.14
(0.01)
(0.13)
0.02
(0.60)
0.48
(0.24)
0.0098
Rate Of Daily Change
1.05
1.0
0.99
1.0
0.99
1.01
0.98
1.24
Day Median Price
3.07
11.15
20.32
11.08
72.16
68.16
13.76
0.05
Price Action Indicator
0.1
(0.01)
(0.07)
0.015
(0.49)
0.53
(0.19)
0.0049
Relative Strength Index
62.82
65.66
63.37
65.92
48.86
54.23
56.41
43.8
Coefficient Of Variation
709.07
623.74
539.92
631.53
8852.86
1323.53
10720.81
3762.74
Mean Deviation
2.82
0.4359
0.509
0.0925
1.51
0.5963
2.54
9.0
Jensen Alpha
0.4173
0.0254
0.1038
0.0086
(0.01)
(0.03)
(0.17)
0.7684
Total Risk Alpha
0.0568
0.0127
0.0332
(0.01)
(0.25)
(0.05)
(0.62)
(1.48)
Sortino Ratio
0.1142
0.023
0.0571
(0.44)
(0.02)
(0.02)
(0.01)
0.0215
Downside Variance
14.76
0.5368
0.7034
0.019
6.72
0.7702
8.71
231.08
Standard Deviation
3.68
0.6063
0.6927
0.1224
2.14
0.814
5.33
15.3
Kurtosis
0.4852
1.95
1.6
1.56
4.64
1.43
39.8
3.94
Potential Upside
6.38
1.03
1.16
0.1833
3.21
1.34
3.32
28.0
Treynor Ratio
0.3895
0.0993
0.5731
0.8764
0.0399
0.0461
0.0132
(0.08)
Maximum Drawdown
18.34
3.2
3.48
0.6399
13.28
4.74
43.7
91.35
Variance
13.56
0.3676
0.4798
0.015
4.56
0.6625
28.42
234.23
Market Risk Adjusted Performance
0.3995
0.1093
0.5831
0.8864
0.0499
0.0561
0.0232
(0.07)
Risk Adjusted Performance
0.0892
0.0924
0.1078
0.0539
0.0138
0.0462
0.0143
0.0248
Skewness
0.3226
(0.75)
(0.54)
0.6332
(1.24)
(0.46)
5.58
0.8937
Semi Deviation
3.1
0.5142
0.6088
0.0
2.54
0.8095
2.74
11.07
Information Ratio
0.1192
0.0277
0.0692
(0.50)
(0.03)
(0.02)
(0.01)
0.0213
Value At Risk
(5.16)
(0.83)
(1.12)
(0.18)
(3.30)
(1.39)
(4.50)
(18.65)
Expected Short fall
(3.25)
(0.48)
(0.52)
(0.14)
(1.37)
(0.61)
(3.16)
(12.21)
Downside Deviation
3.84
0.7327
0.8387
0.1379
2.59
0.8776
2.95
15.2
Semi Variance
9.62
0.2644
0.3706
(0.01)
6.45
0.6554
7.51
122.51

Immutep Competition Performance Charts

Five steps to successful analysis of Immutep Competition

Immutep's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Immutep Ltd ADR in relation to its competition. Immutep's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Immutep in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Immutep's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Immutep Ltd ADR, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Immutep position

In addition to having Immutep in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Casinos Thematic Idea Now

Casinos
Casinos Theme
Companies that are related to providing casino-type services across multiple geographical areas. The Casinos theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Casinos Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Immutep Ltd ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Immutep Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Immutep Ltd Adr Stock. Highlighted below are key reports to facilitate an investment decision about Immutep Ltd Adr Stock:
How To Invest In Immutep
Details
Is Immutep Stock a good investment?
Details
What is Immutep's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Immutep Correlation with its peers.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for Immutep Stock analysis

When running Immutep's price analysis, check to measure Immutep's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immutep is operating at the current time. Most of Immutep's value examination focuses on studying past and present price action to predict the probability of Immutep's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immutep's price. Additionally, you may evaluate how the addition of Immutep to your portfolios can decrease your overall portfolio volatility.
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Global Correlations
Find global opportunities by holding instruments from different markets
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Is Immutep's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immutep. If investors know Immutep will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immutep listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.31)
Revenue Per Share
0.04
Quarterly Revenue Growth
0.252
Return On Assets
(0.26)
Return On Equity
(0.42)
The market value of Immutep Ltd ADR is measured differently than its book value, which is the value of Immutep that is recorded on the company's balance sheet. Investors also form their own opinion of Immutep's value that differs from its market value or its book value, called intrinsic value, which is Immutep's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immutep's market value can be influenced by many factors that don't directly affect Immutep's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Immutep's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immutep is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immutep's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY